Equillium Inc
Company Profile
Business description
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Contact
2223 Avenida De La Playa
Suite 105
La JollaCA92037
USAT: +1 858 240-1200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,787.40 | 41.30 | -0.47% |
| CAC 40 | 7,738.42 | 75.83 | 0.99% |
| DAX 40 | 23,790.11 | 116.82 | 0.49% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,774.69 | 10.64 | -0.12% |
| HKSE | 23,949.83 | 271.58 | -1.12% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,732.63 | 29.85 | -0.08% |
| NZX 50 Index | 12,688.74 | 95.55 | -0.75% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,552.00 | 45.70 | -0.53% |
| SSE Composite Index | 3,450.76 | 4.03 | -0.12% |